In conclusion, our data demonstrated that CD38 deficiency in SMCs protects against AngII-induced AAA formation by attenuating vascular remodeling including the inhibitions of SMC phenotype switch and macrophage infiltration in aortas, suggesting that CD38 may be a potential therapeutic target for AAA formation. The gene discussed is AGT; the disease is triple-A syndrome.